Health Catalyst (NASDAQ:HCAT) Price Target Cut to $3.25 by Analysts at Citigroup

Health Catalyst (NASDAQ:HCAT) had its price target reduced by analysts at Citigroup from $3.50 to $3.25 in a report released on Tuesday,Benzinga reports. The firm currently has a “neutral” rating on the stock. Citigroup’s price target points to a potential upside of 21.00% from the company’s previous close.

Several other equities analysts have also issued reports on HCAT. Evercore ISI cut their price target on Health Catalyst from $4.00 to $3.00 and set an “in-line” rating on the stock in a research note on Wednesday, October 8th. Stifel Nicolaus reduced their price target on shares of Health Catalyst from $4.50 to $3.75 and set a “hold” rating for the company in a report on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Health Catalyst in a research note on Wednesday, October 8th. William Blair restated an “outperform” rating on shares of Health Catalyst in a research note on Tuesday. Finally, UBS Group reissued an “outperform” rating on shares of Health Catalyst in a research report on Tuesday. Five analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $4.36.

Health Catalyst Price Performance

Health Catalyst stock traded down $0.16 during trading hours on Tuesday, hitting $2.69. 714,560 shares of the stock were exchanged, compared to its average volume of 693,101. The business’s 50-day moving average is $3.04 and its two-hundred day moving average is $3.51. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.83 and a current ratio of 1.83. The stock has a market capitalization of $189.01 million, a P/E ratio of -1.79 and a beta of 1.64. Health Catalyst has a 12 month low of $2.52 and a 12 month high of $9.24.

Institutional Trading of Health Catalyst

A number of hedge funds and other institutional investors have recently modified their holdings of HCAT. First Light Asset Management LLC lifted its holdings in Health Catalyst by 99.1% in the first quarter. First Light Asset Management LLC now owns 10,436,807 shares of the company’s stock valued at $47,279,000 after buying an additional 5,195,686 shares during the period. Whetstone Capital Advisors LLC bought a new position in shares of Health Catalyst during the 1st quarter worth approximately $7,724,000. Nuveen LLC acquired a new stake in Health Catalyst in the first quarter worth $2,674,000. Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Health Catalyst by 172.6% in the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 694,361 shares of the company’s stock valued at $3,145,000 after buying an additional 439,599 shares during the period. Finally, Acadian Asset Management LLC lifted its holdings in shares of Health Catalyst by 88.8% in the 1st quarter. Acadian Asset Management LLC now owns 930,229 shares of the company’s stock worth $4,211,000 after purchasing an additional 437,536 shares in the last quarter. Institutional investors own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.